NASDAQ:BLU

BELLUS Health Competitors

$4.45
+0.07 (+1.60 %)
(As of 04/14/2021 12:30 PM ET)
Add
Compare
Today's Range
$4.12
Now: $4.45
$4.46
50-Day Range
$3.65
MA: $4.03
$4.58
52-Week Range
$2.01
Now: $4.45
$12.03
Volume16,856 shs
Average Volume1.39 million shs
Market Capitalization$348.60 million
P/E RatioN/A
Dividend YieldN/A
Beta0.42

Competitors

BELLUS Health (NASDAQ:BLU) Vs. CARA, ACRS, TBPH, STTK, CMPS, and OLMA

Should you be buying BLU stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to BELLUS Health, including Cara Therapeutics (CARA), Aclaris Therapeutics (ACRS), Theravance Biopharma (TBPH), Shattuck Labs (STTK), COMPASS Pathways (CMPS), and Olema Pharmaceuticals (OLMA).

Cara Therapeutics (NASDAQ:CARA) and BELLUS Health (NASDAQ:BLU) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Cara Therapeutics and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cara Therapeutics-360.35%-64.36%-53.22%
BELLUS Health-190,199.98%-30.46%-28.77%

Analyst Recommendations

This is a breakdown of current ratings for Cara Therapeutics and BELLUS Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cara Therapeutics00403.00
BELLUS Health02602.75

Cara Therapeutics currently has a consensus target price of $34.50, indicating a potential upside of 23.30%. BELLUS Health has a consensus target price of $8.6167, indicating a potential upside of 93.63%. Given BELLUS Health's higher possible upside, analysts clearly believe BELLUS Health is more favorable than Cara Therapeutics.

Volatility and Risk

Cara Therapeutics has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Comparatively, BELLUS Health has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500.

Valuation & Earnings

This table compares Cara Therapeutics and BELLUS Health's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cara Therapeutics$19.89 million70.79$-106,370,000.00($2.49)-11.34
BELLUS Health$30,000.0011,619.99$-25,970,000.00($0.55)-8.09

BELLUS Health has lower revenue, but higher earnings than Cara Therapeutics. Cara Therapeutics is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

67.0% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 38.4% of BELLUS Health shares are owned by institutional investors. 5.7% of Cara Therapeutics shares are owned by insiders. Comparatively, 24.2% of BELLUS Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

BELLUS Health beats Cara Therapeutics on 9 of the 14 factors compared between the two stocks.

Aclaris Therapeutics (NASDAQ:ACRS) and BELLUS Health (NASDAQ:BLU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.

Profitability

This table compares Aclaris Therapeutics and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aclaris Therapeutics-941.07%-104.00%-64.47%
BELLUS Health-190,199.98%-30.46%-28.77%

Valuation & Earnings

This table compares Aclaris Therapeutics and BELLUS Health's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclaris Therapeutics$4.23 million340.22$-161,350,000.00($2.25)-12.35
BELLUS Health$30,000.0011,619.99$-25,970,000.00($0.55)-8.09

BELLUS Health has lower revenue, but higher earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

59.1% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 38.4% of BELLUS Health shares are held by institutional investors. 8.2% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 24.2% of BELLUS Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Aclaris Therapeutics and BELLUS Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aclaris Therapeutics0000N/A
BELLUS Health02602.75

BELLUS Health has a consensus price target of $8.6167, indicating a potential upside of 93.63%. Given BELLUS Health's higher possible upside, analysts plainly believe BELLUS Health is more favorable than Aclaris Therapeutics.

Risk and Volatility

Aclaris Therapeutics has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, BELLUS Health has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.

Summary

BELLUS Health beats Aclaris Therapeutics on 9 of the 13 factors compared between the two stocks.

BELLUS Health (NASDAQ:BLU) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares BELLUS Health and Theravance Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BELLUS Health-190,199.98%-30.46%-28.77%
Theravance Biopharma-345.16%N/A-51.60%

Valuation & Earnings

This table compares BELLUS Health and Theravance Biopharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BELLUS Health$30,000.0011,619.99$-25,970,000.00($0.55)-8.09
Theravance Biopharma$73.41 million18.96$-236,460,000.00($4.25)-5.02

BELLUS Health has higher earnings, but lower revenue than Theravance Biopharma. BELLUS Health is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

38.4% of BELLUS Health shares are held by institutional investors. Comparatively, 80.4% of Theravance Biopharma shares are held by institutional investors. 24.2% of BELLUS Health shares are held by insiders. Comparatively, 5.9% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for BELLUS Health and Theravance Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BELLUS Health02602.75
Theravance Biopharma00703.00

BELLUS Health presently has a consensus target price of $8.6167, indicating a potential upside of 93.63%. Theravance Biopharma has a consensus target price of $33.2857, indicating a potential upside of 55.83%. Given BELLUS Health's higher probable upside, equities analysts clearly believe BELLUS Health is more favorable than Theravance Biopharma.

Volatility & Risk

BELLUS Health has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Summary

Theravance Biopharma beats BELLUS Health on 8 of the 14 factors compared between the two stocks.

BELLUS Health (NASDAQ:BLU) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of current ratings for BELLUS Health and Shattuck Labs, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BELLUS Health02602.75
Shattuck Labs00603.00

BELLUS Health presently has a consensus target price of $8.6167, indicating a potential upside of 93.63%. Shattuck Labs has a consensus target price of $45.60, indicating a potential upside of 37.52%. Given BELLUS Health's higher probable upside, equities analysts clearly believe BELLUS Health is more favorable than Shattuck Labs.

Profitability

This table compares BELLUS Health and Shattuck Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BELLUS Health-190,199.98%-30.46%-28.77%
Shattuck LabsN/AN/AN/A

Valuation & Earnings

This table compares BELLUS Health and Shattuck Labs' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BELLUS Health$30,000.0011,619.99$-25,970,000.00($0.55)-8.09
Shattuck LabsN/AN/AN/AN/AN/A

Shattuck Labs has lower revenue, but higher earnings than BELLUS Health.

Institutional and Insider Ownership

38.4% of BELLUS Health shares are held by institutional investors. 24.2% of BELLUS Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

COMPASS Pathways (NASDAQ:CMPS) and BELLUS Health (NASDAQ:BLU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Valuation and Earnings

This table compares COMPASS Pathways and BELLUS Health's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
COMPASS PathwaysN/AN/A$-19,610,000.00N/AN/A
BELLUS Health$30,000.0011,619.99$-25,970,000.00($0.55)-8.09

COMPASS Pathways has higher earnings, but lower revenue than BELLUS Health.

Profitability

This table compares COMPASS Pathways and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
COMPASS PathwaysN/AN/AN/A
BELLUS Health-190,199.98%-30.46%-28.77%

Analyst Recommendations

This is a breakdown of recent ratings for COMPASS Pathways and BELLUS Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
COMPASS Pathways00603.00
BELLUS Health02602.75

COMPASS Pathways currently has a consensus target price of $70.75, indicating a potential upside of 95.33%. BELLUS Health has a consensus target price of $8.6167, indicating a potential upside of 93.63%. Given COMPASS Pathways' stronger consensus rating and higher possible upside, equities research analysts clearly believe COMPASS Pathways is more favorable than BELLUS Health.

Insider and Institutional Ownership

15.8% of COMPASS Pathways shares are held by institutional investors. Comparatively, 38.4% of BELLUS Health shares are held by institutional investors. 24.2% of BELLUS Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

COMPASS Pathways beats BELLUS Health on 6 of the 9 factors compared between the two stocks.

BELLUS Health (NASDAQ:BLU) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Valuation and Earnings

This table compares BELLUS Health and Olema Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BELLUS Health$30,000.0011,619.99$-25,970,000.00($0.55)-8.09
Olema PharmaceuticalsN/AN/AN/AN/AN/A

Olema Pharmaceuticals has lower revenue, but higher earnings than BELLUS Health.

Profitability

This table compares BELLUS Health and Olema Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BELLUS Health-190,199.98%-30.46%-28.77%
Olema PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for BELLUS Health and Olema Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BELLUS Health02602.75
Olema Pharmaceuticals00403.00

BELLUS Health currently has a consensus price target of $8.6167, suggesting a potential upside of 93.63%. Olema Pharmaceuticals has a consensus price target of $60.6667, suggesting a potential upside of 77.49%. Given BELLUS Health's higher probable upside, research analysts plainly believe BELLUS Health is more favorable than Olema Pharmaceuticals.

Institutional and Insider Ownership

38.4% of BELLUS Health shares are owned by institutional investors. 24.2% of BELLUS Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

BELLUS Health beats Olema Pharmaceuticals on 5 of the 9 factors compared between the two stocks.


BELLUS Health Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cara Therapeutics logo
CARA
Cara Therapeutics
1.8$28.23+2.6%$1.37 billion$19.89 million-13.32
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.78+4.8%$1.37 billion$4.23 million-20.58Increase in Short Interest
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.34+3.6%$1.34 billion$73.41 million-4.51Unusual Options Activity
News Coverage
Gap Down
Shattuck Labs logo
STTK
Shattuck Labs
1.5$32.96+2.6%$1.34 billionN/A0.00Analyst Report
Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$36.22+0.4%$1.33 billionN/A0.00Analyst Upgrade
OLMA
Olema Pharmaceuticals
1.6$34.18+5.0%$1.30 billionN/A0.00Increase in Short Interest
Zymeworks logo
ZYME
Zymeworks
1.8$30.70+9.1%$1.29 billion$29.54 million-8.14News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$23.12+1.0%$1.28 billionN/A0.00Insider Selling
Unusual Options Activity
Gap Down
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$39.45+1.2%$1.22 billionN/A-2.82Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.56+4.3%$1.21 billionN/A-19.20
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.89+5.9%$1.21 billion$4.23 million-9.44News Coverage
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$34.50+6.0%$1.20 billionN/A0.00
Innoviva logo
INVA
Innoviva
1.4$11.66+0.3%$1.18 billion$261.02 million5.95
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$26.07+16.5%$1.17 billionN/A0.00Increase in Short Interest
Lockup Expiration
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.55+1.6%$1.17 billion$59.70 million-195.50
NKTX
Nkarta
1.8$37.31+4.7%$1.17 billionN/A0.00Increase in Short Interest
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.42+4.4%$1.13 billion$35.22 million-7.61
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.24+2.6%$1.12 billion$230,000.00-12.20Gap Down
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$17.47+7.5%$1.12 billion$42.12 million-12.94Unusual Options Activity
News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.65+4.0%$1.11 billionN/A-8.97Increase in Short Interest
Omeros logo
OMER
Omeros
1.4$18.18+3.8%$1.08 billion$111.81 million-7.64
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$30.46+0.7%$1.08 billion$57.05 million0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.54+5.1%$1.07 billionN/A-6.98
Zogenix logo
ZGNX
Zogenix
1.7$19.84+3.8%$1.06 billion$3.65 million-2.09
MannKind logo
MNKD
MannKind
1.4$4.43+5.0%$1.05 billion$63.04 million-21.09Increase in Short Interest
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$23.73+7.8%$1.05 billionN/A-8.76Gap Down
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.56+4.5%$1.04 billion$120,000.00-3.91Analyst Upgrade
News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$40.52+2.6%$1.04 billion$20.79 million-13.97Analyst Upgrade
News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$21.47+3.8%$1.04 billionN/A-7.06Increase in Short Interest
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$25.13+3.4%$1.02 billionN/A-8.67
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.78+2.7%$996.70 million$122.47 million-27.90Analyst Downgrade
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$21.47+4.1%$993.66 million$1.52 million-11.42Increase in Short Interest
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.36+0.3%$982.60 million$800.40 million22.98
Prothena logo
PRTA
Prothena
2.1$24.12+3.1%$934.94 million$810,000.00-9.42Increase in Short Interest
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.64+4.5%$918.28 millionN/A-12.74Analyst Upgrade
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$27.46+1.4%$914.76 millionN/A-25.43
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.61+1.8%$895.14 million$227.19 million46.14
Radius Health logo
RDUS
Radius Health
1.1$19.77+4.4%$886.30 million$173.32 million-8.10Gap Down
Annexon logo
ANNX
Annexon
1.9$23.84+3.3%$879.54 millionN/A0.00Increase in Short Interest
Gap Down
Affimed logo
AFMD
Affimed
1.6$10.19+2.9%$873.54 million$23.96 million-17.27Analyst Report
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.46+3.2%$869.64 millionN/A0.00News Coverage
Gap Down
Merus logo
MRUS
Merus
1.6$23.42+3.3%$863.20 million$31.13 million-7.63Analyst Report
Analyst Revision
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$35.81+3.9%$845.56 millionN/A-10.63
Epizyme logo
EPZM
Epizyme
1.8$8.39+2.4%$833.11 million$23.80 million-3.76
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.50+1.0%$822.01 million$322.36 million125.00
Humanigen logo
HGEN
Humanigen
1.7$15.46+1.6%$813.46 millionN/A0.00Analyst Report
Increase in Short Interest
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$24.12+5.0%$806.52 million$296.70 million49.22Gap Down
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.49+3.7%$758.12 million$40.89 million-3.62Analyst Report
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.35+2.8%$750.64 million$322.07 million-5.10Decrease in Short Interest
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$27.17+3.5%$732.39 million$148.36 million-7.06News Coverage
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.